The Dow Jones (^DJI) includes some of the most reliable stocks in the market, and while not all are equal, a few continue to shine. These companies are leveraging their strengths to maintain leadership and reward investors.
Not all Dow Jones stocks are created equal, and StockStory is here to help you find the ones with the most upside. That said, here are three Dow Jones stocks that could be good additions to your portfolio.
Procter & Gamble (PG)
Market Cap: $386.9 billion
Founded by candle maker William Procter and soap maker James Gamble, Proctor & Gamble (NYSE:PG) is a consumer products behemoth whose product portfolio spans everything from facial tissues to laundry detergent to feminine care to men’s grooming.
Why Do We Watch PG?
- Enormous revenue base of $83.93 billion provides significant negotiating leverage in retail partnerships
- Healthy operating margin of 25.2% shows it’s a well-run company with efficient processes
- PG is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders
Procter & Gamble’s stock price of $164.91 implies a valuation ratio of 23.1x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.
Coca-Cola (KO)
Market Cap: $306.2 billion
A pioneer and behemoth in carbonated soft drinks, Coca-Cola (NYSE:KO) is a storied beverage company best known for its flagship soda.
Why Is KO on Our Radar?
- Core business is healthy and doesn’t need acquisitions to boost sales as its organic revenue growth averaged 11.1% over the past two years
- Customer loyalty and massive revenue base of $46.98 billion makes it a household name that influences purchasing decisions
- Products command premium prices and lead to a best-in-class gross margin of 60.6%
Coca-Cola is trading at $71.29 per share, or 23.6x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Merck (MRK)
Market Cap: $195.5 billion
With roots dating back to 1891 and a portfolio that includes the blockbuster cancer immunotherapy Keytruda, Merck (NYSE:MRK) develops and sells prescription medicines, vaccines, and animal health products across oncology, infectious diseases, cardiovascular, and other therapeutic areas.
Why Are We Fans of MRK?
- Unparalleled scale of $63.92 billion in revenue gives it negotiating leverage and staying power in an industry with high barriers to entry
- Free cash flow margin expanded by 11.2 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
- Industry-leading 15.6% return on capital demonstrates management’s skill in finding high-return investments
At $77.90 per share, Merck trades at 8.6x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it’s free.
Stocks We Like Even More
The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free.